Drug intelligence / Profile preview

OMG-100

Development stage: Unknown
Lead developer: OMG Pharma
Modality: Small Molecules
Administration: Oral, Sublingual, Buccal

Overview

OMG-100 is an oral dissolving tablet (ODT) formulation of cannabidiol (CBD) being developed by OMG Pharma for the treatment of insomnia disorder. The product utilizes a proprietary delivery technology designed to enhance the bioavailability and pharmacokinetic profile of CBD by facilitating mucosal absorption in the oral cavity, thereby bypassing first-pass hepatic metabolism. This delivery method aims to provide a faster onset of action and more consistent therapeutic levels compared to traditional oral CBD oils or capsules. OMG-100 is currently being evaluated in clinical trials to assess its safety, tolerability, and efficacy in improving sleep quality and duration in patients with insomnia.

Other names: cannabidiolCBD

Targets

CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on OMG-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMG-100.

Explore the full profile